Both penicillin and amoxycillin should be tested in antimicrobial surveillance for Streptococcus pneumoniae [1]

Clinical Microbiology and Infection

Volumn 11, Issue 5, 2005, Pages 422-423

  Garau, J ^a  

^a HOSPITAL MÚTUA DE TERRASSA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; AUGMENTIN ES 600; AUGMENTIN SR; COTRIMOXAZOLE; MACROLIDE; PENICILLIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; BACTEREMIA; BACTERIUM ISOLATE; CHRONIC BRONCHITIS; CLINICAL TRIAL; COMMUNITY ACQUIRED PNEUMONIA; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG INFORMATION; DRUG MEGADOSE; DRUG PROTEIN BINDING; DRUG SURVEILLANCE PROGRAM; HUMAN; LETTER; MENINGITIS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; OTITIS MEDIA; PENICILLIN RESISTANCE; PRIORITY JOURNAL; SINUSITIS; STREPTOCOCCUS PNEUMONIAE;

EID: 17744367838     PISSN: 1198743X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2005.01130.x     Document Type: Letter

References (9)

1. Cornaglia G, Hrynievicz W, Jarlier V et al. European recommendations for antimicrobial resistance surveillance. Clin Microbiol Infect 2004; 10: 349-383.
2. Jacobs M, Felmingham D, Appelbaum P et al. The Alexander Project 1998-2000: susceptibility of pathogens isolated from community-acquired respiratory tract infection to commonly used antimicrobial agents. J Antimicrob Chemother 2003; 52: 229-246.
3. Bond JM, Lightbown JW, Barber M, Waterworth PM. A comparison of four phenoxypenicillins. BMJ 1963; 2: 956-961.
4. Sutherland R, Croydon EAP, Rolinson GN. Amoxycillin: a new semi-synthetic penicillin. BMJ 1972; 3: 13-16.
5. White A, Kaye C, Poupard J et al. Augmentin (amoxicillin/clavulanate) in the treatment of community-acquired respiratory tract infection: a review of the continuing development of an innovative antimicrobial agent. J Antimicrob Chemother 2004; 53 suppl S1): 3-20.
6. Woodnutt G, Berry V. Two pharmacodynamic models for assessing the efficacy of amoxicillin-clavulanate against experimental respiratory tract infections caused by strains of Streptococcus pneumoniae. Antimicrob Agents Chemother 1999; 43: 29-34.
7. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing, 14th informational supplement. Approved standard M100-S14. Wayne, PA: NCCLS, 2004.
8. Garau J. Performance in practice: bacteriological efficacy in patients with drug-resistant S. pneumoniae. Clin Microbiol Infect 2004; 10(suppl 2): 28-35.
9. Dagan R, Hoberman A, Johnson C et al. Bacteriological and clinical efficacy of high dose amoxycillin/clavulanate in children with acute otitis media. Pediatr Infect Dis J 2001; 20: 829-837.